PISCATAWAY, N.J.—GenScript has signed a biology researchcollaboration with Roche Research & Development Center (RRDC) to provideassay development services for potential drug targets in line with Roche's drugdevelopment portfolio.
Recognizing the distinct advantages that CRO providersoffer, many pharmaceutical companies have adapted an outsourcing strategy toincrease productivity and offset costs.
GenScript is a contract research organization (CRO) focusedin biological research and drug discovery services. Its service portfolioincludes bio-reagent services, assay development & screening, lead optimizationand antibody drug development.
"After the success of medicinal chemistry outsourcing, biologyCRO is becoming a new trend in drug discovery. We expect a fruitfulcollaboration with GenScript in assay development," notes Dr. Li Chen, chiefscientific officer of RRDC in China.
Dr. Frank Zhang, CEO of GenScript, points out that being thefirst drug discovery based R&D center established in China by a leadingmultinational pharmaceutical company, RRDC is taking the lead again inexpanding into discovery biology arena.
"We appreciate the confidence that RRDC has shown in GenScript,and believe that the collaboration will mutually benefit us," he adds.
